NCT03413722 - Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

August 1, 2021

Study Completion Date

October 1, 2022

Conditions

End Stage Renal Disease

Interventions

DRUG

Tacrolimus

The patient's physician will prescribe drug according to standard practice.

DRUG

Everolimus

The patient's physician will prescribe drug according to standard practice.

Trial Locations (1)

University of Kansas Medical Center, Kansas City